Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Telix Pharmaceuticals Ltd. has shared promising results from their ProstACT SELECT trial, showing a median radiographic progression-free survival of 8.8 months for their TLX591 therapy in treating metastatic castrate-resistant prostate cancer. TLX591, a lutetium-labelled radio-antibody drug conjugate, also demonstrated a favorable safety profile and is now advancing to a Phase III trial. The company emphasizes TLX591’s potential benefits, including a patient-friendly dosing regimen and lower radiation exposure compared to existing treatments.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.